Literature DB >> 9784526

Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice.

R K Sellon1, S Tonkonogy, M Schultz, L A Dieleman, W Grenther, E Balish, D M Rennick, R B Sartor.   

Abstract

Mice with targeted deletion of the gene for interleukin-10 (IL-10) spontaneously develop enterocolitis when maintained in conventional conditions but develop only colitis when kept in specific-pathogen-free (SPF) environments. This study tested the hypothesis that enteric bacteria are necessary for the development of spontaneous colitis and immune system activation in IL-10-deficient mice. IL-10-deficient mice were maintained in either SPF conditions or germfree conditions or were populated with bacteria known to cause colitis in other rodent models. IL-10-deficient mice kept in SPF conditions developed colitis in all segments of the colon (cecum and proximal and distal colon). These mice exhibited immune system activation as evidenced by increased expression of CD44 on CD4(+) T cells; increased mesenteric lymph node cell numbers; and increased production of immunoglobulin A (IgA), IgG1, and IL-12 p40 from colon fragment cultures. Mice populated with bacterial strains, including Bacteroides vulgatus, known to induce colitis in other rodent models had minimal colitis. Germfree IL-10-deficient mice had no evidence of colitis or immune system activation. We conclude therefore that resident enteric bacteria are necessary for the development of spontaneous colitis and immune system activation in IL-10-deficient mice.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9784526      PMCID: PMC108652     

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  54 in total

1.  Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12.

Authors:  R Duchmann; E Schmitt; P Knolle; K H Meyer zum Büschenfelde; M Neurath
Journal:  Eur J Immunol       Date:  1996-04       Impact factor: 5.532

2.  Biochemical characterization and cellular distribution of a polymorphic, murine cell-surface glycoprotein expressed on lymphoid tissues.

Authors:  I S Trowbridge; J Lesley; R Schulte; R Hyman; J Trotter
Journal:  Immunogenetics       Date:  1982-03       Impact factor: 2.846

3.  Lipoteichoic acid preparations of gram-positive bacteria induce interleukin-12 through a CD14-dependent pathway.

Authors:  M G Cleveland; J D Gorham; T L Murphy; E Tuomanen; K M Murphy
Journal:  Infect Immun       Date:  1996-06       Impact factor: 3.441

4.  Interleukin-10-deficient mice develop chronic enterocolitis.

Authors:  R Kühn; J Löhler; D Rennick; K Rajewsky; W Müller
Journal:  Cell       Date:  1993-10-22       Impact factor: 41.582

5.  Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease.

Authors:  S Schreiber; T Heinig; H G Thiele; A Raedler
Journal:  Gastroenterology       Date:  1995-05       Impact factor: 22.682

6.  Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR).

Authors:  M Niessner; B A Volk
Journal:  Clin Exp Immunol       Date:  1995-09       Impact factor: 4.330

7.  Mechanisms of acute and chronic intestinal inflammation induced by indomethacin.

Authors:  T Yamada; E Deitch; R D Specian; M A Perry; R B Sartor; M B Grisham
Journal:  Inflammation       Date:  1993-12       Impact factor: 4.092

8.  Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation.

Authors:  M Cella; D Scheidegger; K Palmer-Lehmann; P Lane; A Lanzavecchia; G Alber
Journal:  J Exp Med       Date:  1996-08-01       Impact factor: 14.307

9.  The route of enteric infection in normal mice.

Authors:  P B Carter; F M Collins
Journal:  J Exp Med       Date:  1974-05-01       Impact factor: 14.307

10.  The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats.

Authors:  J D Taurog; J A Richardson; J T Croft; W A Simmons; M Zhou; J L Fernández-Sueiro; E Balish; R E Hammer
Journal:  J Exp Med       Date:  1994-12-01       Impact factor: 14.307

View more
  540 in total

Review 1.  The SAMP1/Yit mouse: another step closer to modeling human inflammatory bowel disease.

Authors:  W Strober; K Nakamura; A Kitani
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

2.  Intestinal stasis associated bowel inflammation.

Authors:  Shunichiro Komatsu; Yuji Nimura; D Neil Granger
Journal:  World J Gastroenterol       Date:  1999-12       Impact factor: 5.742

3.  Increased expression of Toll-like receptor (TLR) 2 and TLR4 in the colonic mucosa of children with inflammatory bowel disease.

Authors:  B Szebeni; G Veres; A Dezsõfi; K Rusai; A Vannay; M Mraz; E Majorova; A Arató
Journal:  Clin Exp Immunol       Date:  2007-11-07       Impact factor: 4.330

4.  Bifidobacterium animalis causes extensive duodenitis and mild colonic inflammation in monoassociated interleukin-10-deficient mice.

Authors:  James P Moran; Jens Walter; Gerald W Tannock; Susan L Tonkonogy; R Balfour Sartor
Journal:  Inflamm Bowel Dis       Date:  2009-07       Impact factor: 5.325

5.  The epigenetic regulator Uhrf1 facilitates the proliferation and maturation of colonic regulatory T cells.

Authors:  Yuuki Obata; Yukihiro Furusawa; Takaho A Endo; Jafar Sharif; Daisuke Takahashi; Koji Atarashi; Manabu Nakayama; Satoshi Onawa; Yumiko Fujimura; Masumi Takahashi; Tomokatsu Ikawa; Takeshi Otsubo; Yuki I Kawamura; Taeko Dohi; Shoji Tajima; Hiroshi Masumoto; Osamu Ohara; Kenya Honda; Shohei Hori; Hiroshi Ohno; Haruhiko Koseki; Koji Hase
Journal:  Nat Immunol       Date:  2014-04-28       Impact factor: 25.606

6.  Prevention of acetic acid-induced colitis by desferrithiocin analogs in a rat model.

Authors:  Raymond J Bergeron; Jan Wiegand; William R Weimar; John Nhut Nguyen; Charles A Sninsky
Journal:  Dig Dis Sci       Date:  2003-02       Impact factor: 3.199

7.  Elimination of local macrophages in intestine prevents chronic colitis in interleukin-10-deficient mice.

Authors:  Norihiko Watanabe; Koichi Ikuta; Kazuichi Okazaki; Hiroshi Nakase; Yasuhiko Tabata; Minoru Matsuura; Hiroyuki Tamaki; Chiharu Kawanami; Tasuku Honjo; Tsutomu Chiba
Journal:  Dig Dis Sci       Date:  2003-02       Impact factor: 3.199

8.  Dysbiosis in inflammatory bowel disease.

Authors:  C P Tamboli; C Neut; P Desreumaux; J F Colombel
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

9.  Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis.

Authors:  T Mimura; F Rizzello; U Helwig; G Poggioli; S Schreiber; I C Talbot; R J Nicholls; P Gionchetti; M Campieri; M A Kamm
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

10.  Systemic antibodies towards mucosal bacteria in ulcerative colitis and Crohn's disease differentially activate the innate immune response.

Authors:  E Furrie; S Macfarlane; J H Cummings; G T Macfarlane
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.